Introduction {#s1}
============

Induced sputum is the gold standard for assessing the pattern of airway inflammation in asthma and its use for inflammatory phenotyping is advocated in the European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines on severe asthma \[[@C1]\].

Since the first standardised protocols for sampling induced sputum, two methods of processing have evolved. The "plug selection method" involves selection of all viscid or denser parts of the sample, while the entire sample, including variable amounts of saliva, is processed using the "whole sputum method" \[[@C2], [@C3]\]. Both collection methods have been found to yield similar results for cell differential count, however no studies have compared the two methods with regards to mRNA expression \[[@C4]\].

The six-gene expression signature (6GS) is an mRNA-based gene signature that was developed as a molecular diagnostic tool to provide a clinically feasible method for inflammatory phenotyping of asthma; however, implementation in clinical practice has been hampered by the immediate requirements of processing induced sputum to stabilise RNA for gene expression analyses \[[@C5]\].

Easy-to-use mRNA-stabilising kits are commercially available and potentially offer huge advantages over the current processing protocols as they provide stabilisation of the sample upon collection (using an RNA-stabilising buffer), thereby removing the immediate need for sample processing. However, whether these kits can allow accurate reflection of airway inflammation is unknown. Further, in contrast to the "plug selection method" employed by most groups assessing mRNA expression in induced sputum \[[@C5]--[@C7]\], these kits rely on sampling sputum using the "whole sputum method" and the implications of increased contamination with salivary cells on RNA composition and the diagnostic utility of the sample is unknown \[[@C2], [@C3]\].

We believe validation of an easy-to-use kit providing immediate mRNA stabilising is key to developing a clinically feasible method for inflammatory phenotyping and biobanking outside highly specialised centres. Therefore, the aim of this study was to compare 6GS gene expression measured on sputum collected using the "whole sample method" in an mRNA-stabilising kit with sputum collected using the "plug selection method".

Further, to assess whether this new methodology accurately reflected airway inflammation, we wanted to compare the ability of the two collection methods to discriminate inflammatory phenotypes of asthma using expression of the 6GS. We hypothesised that sputum collected using the "whole sample method" in an mRNA-stabilising kit was non-inferior to sputum collected using the "plug selection method" with regards to RNA yield, levels of gene expression of 6GS and the ability of 6GS to discriminate inflammatory phenotypes of asthma.

Methods {#s2}
=======

Two separate sputum samples were collected from 27 asthma patients referred for evaluation of asthma at the Respiratory Outpatient Clinic at Bispebjerg Hospital, Denmark, who all participated in the BREATHE (Biomarker Research and E-Health Advancements To Help Everyone) study (ethical approval: H-16047428).

Criteria for participation were respiratory symptoms (*e.g.* dyspnoea, cough, wheezing or chest tightness) and 1) either a current positive bronchial challenge test or 2) a doctor\'s diagnosis of asthma and a current asthma maintenance therapy corresponding to step 4 or 5 in the 2017 Global Initiative for Asthma guidelines.

One sputum sample was collected in an Oragene-RNA RE 100-vial (DNA Genotek; Ontario, Canada) using the "whole sputum method" and one sputum sample was collected in a Petri dish and processed using the "plug selection method". The Oragene-RNA RE 100 kit is commercially available and has been developed for collection and preservation of mRNA in saliva for research purposes. The vial can contain a sample of up to 2 mL and holds the sample stable at room temperature for 60 days.

Sputum induction {#s2a}
----------------

Sputum was collected after a bronchial challenge test with mannitol. Sputum was induced using isotonic saline if forced expiratory volume in 1 s (FEV~1~) was \<70% of predicted \[[@C8]\].

The mannitol challenge involved inhalation of incremental doses of mannitol and the patients were instructed to cough and expectorate sputum after each inhalation. Spirometry was measured 1 min after each dose and the test was completed when a 15% decline from baseline FEV~1~ was recorded or when reaching a cumulative dose of 635 mg \[[@C9], [@C10]\].

Sputum handling {#s2b}
---------------

Both sputum samples were collected on the same day and within the same induction. First, the patient provided a sample for the "plug selection method", which was collected in a specimen jar (Petri dish). This sample was continuously evaluated by a trained lab technician and when considered to be of sufficient size and quality, all subsequent expectorated sample was collected using the "whole sputum method" in the Oragene-RNA RE 100-vial kit.

### Handling using the "plug selection method" {#s2b1}

The sputum sample was processed within 1 h of collection as described by B[afadhel]{.smallcaps} *et al*. \[[@C11]\] and a minimum of two plugs were selected depending on the quantity of the sputum sample: one for cell differential count (CDC), which was dispersed with dithiothreitol and one stored in RLT buffer and frozen at −80°C for later gene expression analysis. When restricted by sample quantity, the CDC was prioritised.

### Handling using the "whole sputum method" {#s2b2}

The entire sample was collected using the "whole sputum method" in an Oragene-RNA RE-100 kit as per manufacturer\'s instructions (DNA Genotek, Ottawa, Canada.). Upon closure of the vial cap, a non-specified stabilising liquid was released from the cap and the capped vial was shaken for 10 s. No additional handling or processing was done, and the sample was stored at −40°C for subsequent gene expression analysis.

Sputum gene expression analyses {#s2c}
-------------------------------

The whole sputum collected in the Oragene-RNA RE 100-vial kit required several processing steps before RNA extraction in accordance with the accompanying protocol (DNA Genotek) \[[@C12]\]. This included an initial incubation at 50°C for 1 h, addition of Oragene RNA neutraliser solution and cold 95% ethanol, centrifugation and resuspension of the resulting pellet in RLT buffer.

RNA extraction of samples in RLT buffer, including a DNase step, was then performed using an automated method (QIAcube) with the RNeasy Mini Kit as per manufacturer\'s instructions and as previously published (QIAGEN; Hilden, Germany) \[[@C5]\]. RNA quantity was measured using the Nanodrop (Thermo Fisher, Waltham, USA). Up to 200 ng RNA was converted to cDNA using reverse transcriptase, and 6GS expression (*CLC*, *CPA3*, *DNASE1L3*, *IL1B*, *ALPL*, *CXCR2*) was measured by qPCR using standard TaqMan methods. Expression of 6GS was assessed in each sample and the change (Δ) in cycle threshold (CT) for each gene was calculated relative to housekeeping gene 18 s \[[@C13]\].

RNA samples were considered adequate if the level of 18 s housekeeping gene expression was \<22 CT.

Sputum cell differential count {#s2d}
------------------------------

The sputum CDC was performed on a light microscope by an experienced lab technician at Bispebjerg University Hospital, Copenhagen, Denmark. Cell viability was evaluated using the Trypan blue exclusion method. Cut-off values for eosinophilia and neutrophilia were set to ≥3% and \>61%, respectively, based on the CDC and patients were classified as eosinophilic if they had sputum eosinophils ≥3%, and neutrophilic if their sputum neutrophils were ≥61% \[[@C5], [@C11]\].

Clinical assessments {#s2e}
--------------------

Atopy (allergic sensitisation) was defined as a specific IgE \>0.35 kU·L^−1^ for a minimum of 1 out of 10 tested aeroallergens \[[@C14]\]. Spirometry was conducted in accordance with ERS guidelines and a MasterScreenPneumo spirometer (BD Jaeger, Würzburg, Germany) was used for spirometry \[[@C15]\]. Predicted values were calculated with the use of the National Health and Nutrition Examination Survey reference data \[[@C16]\]. Exhaled nitrogen oxide fraction (*F*~ENO~) measurements were done using the Niox Vero (Circassia Limited, Oxford, UK) \[[@C17]\].

Blood eosinophilia was assessed by the Bispebjerg Hospital pathology laboratory using automated flow cytometry with a Sysmex XN 9000 (Sysmex Europe GmbH, Norderstedt, Germany) and blood eosinophilia was defined as a blood eosinophil count ≥0.3×10^9^·L^−1^.

Statistics {#s2f}
----------

SAS Enterprise guide version 7.1 (SAS Institute, Cary, NC, USA) was used for data analysis. Means (SD) are presented for normally distributed data and medians (quartile 1; quartile 3) are presented for non-parametric data.

Statistical analysis was done on the delta CT changes (2^−ΔCT^) between the target gene of interest and the housekeeping gene 18 s \[[@C13]\].

The two methods were compared on expression level using intraclass correlation (ICC). ICC estimates were calculated by an absolute-agreement, two-way mixed-effects model (k=2).

Subsequently the expression of each gene individually was evaluated using the Bland--Altman approach; a method specifically developed to describe agreement between two quantitative measurements using limits of agreement to quantify agreement \[[@C18]\]. We calculated these statistical limits using the logarithmic (log~10~) ΔCT changes (2^−ΔCT^).

Multiple logistic regression was used to calculate the predicted value of a subject having a given phenotype based on their level of expression for each method independently using the delta CT changes (2^−ΔCT^) \[[@C5]\]. Receiver operating characteristic (ROC) curves were generated, and the area under the curve (AUC) was calculated. The respective ROC curves were compared using a Chi-squared test.

Classification of inflammation using gene expression was calculated from the multiple logistic regression models, where the optimal cut-off point for each ROC curve was calculated. We assessed two different methods for calculating the optimal cut-off point; one where the optimal cut-off point was defined as the point on the ROC curve with the minimum distance to the upper left corner (the Euclidian distance):where sensitivity=1 and specificity=1; and one defined as the point for which sensitivity and specificity is maximal (Youden index). We found identical cut-off points for all ROC curves using the two methods.

We then calculated the sensitivity, specificity, PPV and NPV for each method relative to the gold standard (CDC). Finally, we calculated Cohen\'s kappa coefficient for each method to evaluate the agreement in classification between the respective methods and the CDC classification.

Results {#s3}
=======

Study population {#s3a}
----------------

A total of 20 patients (74%) were included in the analyses of gene expression, as 7 patient sample pairs were excluded due to insufficient RNA (determined as weak (\>22)18 s CT housekeeping values; see [figure 1](#F1){ref-type="fig"})). One (5%) patient had sputum collected after induction with isotonic saline, whereas all other patients had sputum collected after a mannitol challenge test. Patient characteristics are summarised in [table 1](#TB1){ref-type="table"}*.* The mean age was 39 years ([sd]{.smallcaps} 19) and 55% of the patients were male. The mean FEV~1~% predicted was 93 ([sd]{.smallcaps} 20) and the median budesonide-equivalent inhaled corticosteroid dose was 800 (600, 800). Forty-five percent of the patients were atopic, while the median level of IgE was 62 (20, 217). The median level of blood eosinophils was 0.13 (0.09, 0.29), sputum eosinophil levels were 2.6 (0.9, 4.5), and *F*~ENO~ was median (interquartile range) 15 (8, 23). There were nine patients (45%) with eosinophilic airway inflammation, five patients (25%) with neutrophilic airway inflammation and three (15%) of these who had both eosinophilic and neutrophilic inflammation.

![Flow chart describing the population of patients used for analysis. *C*~t~: cycle threshold.](00280-2019.01){#F1}

###### 

Patient characteristics

  ------------------------------------------------ -------------------
  **Patients n**                                           20
  **Females**                                              45%
  **Age years**                                           39±19
  **Smoking history pack-years**                        0 (0--5)
  **Daily ICS dose µg of budesonide equivalent**     800 (600--800)
  **Pre-bronchodilator FEV~1~ % pred**                    93±20
  **Pre-bronchodilator FVC % pred**                      104±15
  ***F*~ENO~ ppb**                                     15 (8--23)
  **Atopy^\#^ column**                                     45%
  **Total IgE 10^3^**                                 62 (20--217)
  **Blood eosinophils ×10^9^ kU·L^−1^**             0.13 (0.09--0.29)
  **Sputum subtype n (%)**                         
   Eosinophilic                                          9 (45)
   Neutrophilic                                          5 (25)
  **Sputum eosinophils**                             2.6 (0.9--4.5)
  **Sputum neutrophils**                               36 (17--68)
  ------------------------------------------------ -------------------

Data are presented as mean±[sd]{.smallcaps} or median (interquartile range), unless otherwise stated. ICS: inhaled corticosteroid; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity; *F*~ENO~: exhaled nitrogen oxide fraction. ^\#^: defined as a positive radioallergosorbent test (RAST) for 10 standard aeroallergens.

Expression of target genes {#s3b}
--------------------------

We found a significantly (p\<0.001) higher median RNA concentration in the whole sampled sputum (47.6 (25.1, 132.0)) ng·µL^−1^ compared to the sputum collected using the "plug selection method" (5.1 ng·µL^−1^ (3.5, 6.9)). As listed in [table 2](#TB2){ref-type="table"}, median expression of all target genes was higher in the whole sampled sputum with the neutrophilic gene *ALPL*, and to a lesser extent the eosinophilic gene *DNASE1L3*, having markedly larger difference in expression as illustrated in [table 2](#TB2){ref-type="table"} \[[@C5], [@C19]\]. For all genes, as well as for the RNA concentration, we found a good-to-excellent inter-method reliability as measured by ICC; the gene (*ALPL*) with the biggest difference in expression also had the lowest ICC \[[@C20]\].

###### 

Comparison of RNA concentration and gene expression across methods

                                    **Manually selected plugs**   **Whole sample sputum**    **Intraclass correlation**
  --------------------------------- ----------------------------- ------------------------- ----------------------------
  **RNA concentration ng·µL^−1^**   5.10 (3.5--6.9)               47.6 (25.1--132.0)                    0.93
  ***CLC* expression**              0.09 (0.01--0.33)             0.15 (0.07--0.54)                     0.84
  ***CPA3* expression**             0.07 (0.02--0.33)             0.20 (0.00--0.60)                     0.81
  ***DNASE1L3* expression**         0.26 (0.11--0.50)             0.39 (0.23--5.3)                      0.91
  ***IL1B* expression**             52.6 (32.2--107.0)            114 (49.5--246.4)                     0.77
  ***ALPL* expression**             1.8 (0.62--4.83)              4.84 (1.80--9.34)                     0.74
  ***CXCR2* expression**            5.63 (3.66--24.3)             12.32 (6.93--19.0)                    0.83

Data are presented as median (interquartile range) unless otherwise stated. Gene expression presented as cycle threshold change (2^−ΔCT^) multiplied by 10 000.

Using the Bland--Altman approach, we plotted the difference between the two methods against the mean as shown in [figure 2](#F2){ref-type="fig"}. Across all assessed genes we found five (4%) observations outside the limits of agreement (illustrated by the dashed red line in [figure 2](#F2){ref-type="fig"}), which by convention is what is to be expected (mean of the difference ±2×[sd]{.smallcaps}). The plot for *CLC* could reflect a trend towards increasing mean resulting in a decrease in difference, while the plot for *ALPL* suggest that the lowest means were associated with the largest differences. We found no apparent patterns in the other plots.

![Bland--Altman plots of gene expression. a) *CLC*, b) *CPA3*, c) *DNASE1L3*, d) *IL1B*, e) *ALPL* and f) *CXCR2*. Blue: ref.; solid red: mean of the difference; dashed red: limits of agreement; dashed green: ±3×[sd]{.smallcaps} of the mean of the differences.](00280-2019.02){#F2}

Prediction of inflammatory phenotypes using 6GS {#s3c}
-----------------------------------------------

The CDC obtained from the manually selected plugs was used as the gold standard for classification of inflammatory phenotype (eosinophilic: n=9; neutrophilic: n=5). Sputum differential count was available for 18 of the 20 patients and patients without a CDC were excluded for the analysis of inflammatory phenotype prediction ([figure 1](#F1){ref-type="fig"}).

### Discriminating eosinophilic asthma from non-eosinophilic asthma {#s3c1}

The 6GS resulting from the "plug selection method" ([figure 3a](#F3){ref-type="fig"}; AUC 85%, p=0.1) and "whole sputum method" ([figure 3a](#F3){ref-type="fig"}; AUC 100%, p=0.01) was able to discriminate patients with eosinophilic asthma from patients with non-eosinophilic asthma. Despite this, discrimination was only significant for the whole sampled sputum and we did not find a statistically significant difference between the two ROC curves (p=0.14).

![Receiver operating characteristic (ROC) curves for predicting inflammatory phenotype using the six-gene signature. a) Eosinophilic (EOS) asthma *versus* non-eosinophilic (nonEOS) asthma. b) Neutrophilic (NEU) asthma *versus* non-neutrophilic (nonNEU) asthma.](00280-2019.03){#F3}

We found fair agreement (kappa coefficients of 0.36 (p\<0.001)) for discriminating eosinophilic asthma from non-eosinophilic asthma using 6GS for the manually selected plugs and a substantial agreement (kappa coefficient 0.68 (p\<0.001)) for the whole sampled sputum when comparing to gold-standard classification based on the CDC ([table 3](#TB3){ref-type="table"}) \[[@C21], [@C22]\].

###### 

Discrimination of inflammatory phenotypes using gene expression

                                                              **AUC**   **p-value**   **Cut-off point**   **Sens**   **Spec**   **PPV**   **NPV**   **Kappa**
  ---------------------------------------------------------- --------- ------------- ------------------- ---------- ---------- --------- --------- -----------
  **Eosinophilic asthma *versus* non-eosinophilic asthma**                                                                                         
   Manual plugs                                                0.85         0.1             0.39             56         80        71        67        0.22
   Whole sample                                                1.00        0.01             0.99             67        100        100       77        0.72
  **Neutrophilic asthma *versus* non-neutrophilic asthma**                                                                                         
   Manual plugs                                                1.00        0.008            0.99             80        100        100       93        0.68
   Whole sample                                                0.84         0.2             0.62             80        100        100       93        0.68

All measures are relative to the classification from the manual cell differential count. AUC: area under the curve; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: negative predictive value; Kappa: Cohen\'s kappa coefficient for agreement with the gold-standard classification based on the cell differential count.

The whole sampled sputum had a higher sensitivity, specificity and both PPV and NPV than the manually selected plugs ([table 3](#TB3){ref-type="table"}). Comparing the plugs selected and whole sample method directly gave a kappa coefficient of 0.67 (p\<0.001).

### Discriminating neutrophilic asthma from non-neutrophilic asthma {#s3c2}

The 6GS resulting from manually selected plugs ([figure 3b](#F3){ref-type="fig"}; AUC 100%, p=0.008) and whole sampled sputum ([figure 3b](#F3){ref-type="fig"}; AUC 85%, p=0.2) was able to discriminate patients with neutrophilic asthma from patients with non-neutrophilic asthma. Despite this, discrimination was only significant for the manually selected plugs and we did not find a statistically significant difference between the two ROC curves (p=0.33).

We found substantial agreement in discrimination of neutrophilic asthma from non-neutrophilic asthma using both methods compared with the gold-standard classification based on the CDC ("plug selection method": kappa coefficient of 0.85 (p\<0.001); "whole sputum method": kappa coefficient of 0.85 (p\<0.001)) ([table 3](#TB3){ref-type="table"}) \[[@C21], [@C22]\].

The two methods had identical sensitivity, specificity and PPV and NPV ([table 3](#TB3){ref-type="table"}). Comparing the plugs and whole sample method directly gave a kappa coefficient of 0.69 (p\<0.001).

Discussion {#s4}
==========

We found sputum collected using the "whole sputum method" in an mRNA-stabilising kit to yield more RNA and have a consistently higher level of gene expression across all genes compared with sputum processed using the "plug selection method". Further, we found the two methods to agree and to have a good-to-excellent reliability \[[@C20], [@C23]\]. Finally, expression of the 6GS using both methods performed well in the identification of the inflammatory phenotypes, although the sample collected using the "whole sputum method" in the mRNA-stabilising kit had an improved detection of eosinophilic inflammation.

Compared to our previous work using the 6GS ("plug sputum method") to discriminate inflammatory phenotypes, we found the 6GS to be similarly accurate in discriminating inflammatory phenotypes of asthma using both of the assessed methods \[[@C5]\]. However, as the study was powered to compare gene expression levels rather than discriminate inflammatory phenotypes, these results are limited by the small sample size and future studies validating these findings are warranted.

While the "plug sputum method" is employed by most research groups assessing mRNA expression in sputum \[[@C5]--[@C7]\], no other studies have reported analysis of mRNA in sputum collected using the "whole sputum method". However, the two methods of sputum collection, despite only few studies comparing them directly in terms of differential cell count, have been found to yield similar results, although a higher viability of cells has been reported using the "whole sputum method" \[[@C4], [@C24]\].

Seventy-five percent (n=20) of the included patients had sufficient quality of samples ([figure 1](#F1){ref-type="fig"}) to be included in the analysis of RNA yield and comparison of mRNA expression. Of these, 18 had a plug enabling a CDC ([figure 1](#F1){ref-type="fig"}). While exclusion of 33% of patients due to insufficient sputum samples is unfortunate, and may have introduced a selection bias, we do not believe that it reflects a poor external validity as this issue is universally recognised, as exemplified by just 44% of sputum samples fit for analysis in the U-BIOPRED cohort \[[@C25]\].

Sputum for both processing methods was collected on the same day and after only one induction. We chose this approach, rather than collecting each sample after a separate induction, based on the reports of changes in sputum cellularity after repeated sputum induction within up to 48 h \[[@C26], [@C27]\]. While it might have been optimal to collect the samples after separate inductions on different days, as the differential cell count has been reported to be reproducible within a week using both the "whole sputum method" \[[@C28]\] and the "plug selection method" \[[@C29]\], we chose to do it on the same day due to practicality. As such, we may have introduced a bias, given the fixed order of sample collection; the first sample (collected using the "plug selection method") may be subject to more contamination from the upper airways than the second sample.

We found a higher RNA yield and a consistently higher level of gene expression across all genes in the sputum collected using the "whole sputum method" in an mRNA-stabilising kit. This may to some extent reflect the larger amount of sample collected using the "whole sputum method", including contamination with saliva \[[@C3], [@C4]\]. However, the standardisation relative to a housekeeping gene should mitigate this effect and we believe that the immediate stabilisation of the sample in an mRNA-stabilising buffer is the main reason for this difference. In contrast, the sample processing using the standard "plug selection method" protocol may be stored for up to 2 h before processing, which in turn may result in a significant degradation of mRNA.

Our findings demonstrate that sputum collected using the "whole sputum method" and immediately stabilised using an mRNA-stabilising kit is a reliable method for inflammatory phenotyping that yields comparable or even superior results, compared to the "plug selection method" using a standard sputum processing protocol. As collection of sputum using this method requires neither immediate handling nor laboratory facilities at the site of collection, it could potentially provide inflammatory phenotyping of asthma at a much larger scale than is currently possible. Further, it provides a feasible method for biobanking of airway samples in clinical trials and could be pivotal in large-scale multicentre studies, where the logistical challenges of the manual plug selection may impede its use. Similarly, it could play a key role in facilitating clinically feasible inflammatory phenotyping and biobanking in the increasing number of severe asthma registries, which represent unique prospective real-life cohorts of patients where targeted therapies are initiated, evaluated and interchanged.

In conclusion, sputum collected using the "whole sputum method" in an RNA-stabilising kit is a simple method that obviates the need for immediate handling and provides a clinically feasible method for inflammatory phenotyping and biobanking in clinical care, as well as in large-scale clinical studies.

Further, our findings warrant future studies comparing the "whole sputum method" and "the plug selection method" for gene expression analysis; both with and without the use of RNA-stabilising kits.
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